13.64
Compass Pathways Plc Adr (CMPS) 最新ニュース
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up - Yahoo Finance
Compass Pathways stock falls on Phase 3 trial data release - Investing.com
Compass Pathways reports 6-month data from phase 3 TRD trial - Investing.com
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline - Sahm
Why is Compass Pathways stock gaining today? By Investing.com - Investing.com South Africa
Why is Compass Pathways stock gaining today? - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? - TradingView
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 - TradingView
Enterprise value to EBIT forward of COMPASS Pathways Plc Sponsored ADR – MUN:5Y6 - TradingView
Compass Pathways stock hits 52-week high at 14.77 USD By Investing.com - Investing.com South Africa
Compass Pathways stock hits 52-week high at 14.77 USD - Investing.com
COMPASS Pathways Plc Sponsored ADR Actuals & Estimates (NASDAQ:CMPS) - TradingView
Compass Pathways earnings on deck as psychedelic approval nears - Investing.com
Why is Compass Pathways stock surging 9% today? By Investing.com - Investing.com India
Why is Compass Pathways stock surging 9% today? - Investing.com
Compass Pathways stock hits 52-week high at 12.48 USD By Investing.com - Investing.com South Africa
Compass Pathways stock hits 52-week high at 12.48 USD - Investing.com
Compass Pathways elects Kathleen Tregoning to board By Investing.com - Investing.com South Africa
Compass Pathways elects Kathleen Tregoning to board - Investing.com
CMPSCompass Pathways Plc ADR Stock Price and Quote - Finviz
COMPASS Pathways Plc Q1 2026 Earnings: Narrower Loss Provides Hope Amid Pre-Revenue StageLow Growth Earnings - Newser
Wolfe Research initiates Compass Pathways stock with outperform rating - Investing.com
Compass Pathways stock hits 52-week high at 11.65 USD - Investing.com
Compass Pathways stock hits 52-week high at 11.65 USD By Investing.com - Investing.com India
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins - Yahoo Finance
Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Sahm
Is Compass Pathways (CMPS) outperforming other medical stocks this year? - MSN
Compass Pathways Reports Strong Q1 Results, Shares Surge - Sahm
Why COMPASS Pathways (CMPS) Is Up 13.1% After FDA Fast-Track Moves For COMP360 Profit Shift - Sahm
Compass Pathways stock hits 52-week high at 10.22 USD - Investing.com India
Compass Pathways Q1 Earnings Call Highlights - Barchart.com
Compass Pathways stock surges 8% on beating estimates as FDA accelerates review - Investing.com India
Compass Pathways stock surges 8% on beating estimates as FDA accelerates review By Investing.com - Investing.com South Africa
What makes COMPASS Pathways PLC sponsored ADR (CMPS) a strong momentum stock: Buy now? - MSN
How much upside is left in COMPASS Pathways (CMPS)? Wall Street analysts think 136% - MSN
Compass Pathways earnings on deck as psychedelic approval nears By Investing.com - Investing.com South Africa
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
大文字化:
|
ボリューム (24 時間):